Alector, Inc. ALEC

ALEC Company Overview

Alector, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases and certain forms of cancer through modulation of the immune system. The company operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on immuno-neurology, a field that combines immunology and neuroscience to address diseases such as Alzheimer’s disease, frontotemporal dementia (FTD), and other neurodegenerative conditions. Alector’s core strategy centers on targeting innate immune pathways, particularly microglial function in the central nervous system, to influence disease progression rather than only treating symptoms.

The company’s primary revenue sources have historically included collaboration agreements, research funding, and licensing arrangements, particularly its strategic partnerships with GlaxoSmithKline plc (GSK) and AbbVie Inc. Alector was founded in 2013 by Arnon Rosenthal, Gary Romano, and Wim Parys, and is headquartered in South San Francisco, California. Since its founding, the company has evolved from an early-stage research platform into a publicly traded biotechnology company advancing multiple clinical-stage therapeutic candidates, including progranulin-elevating therapies and TREM2-targeting antibodies designed to address genetically defined neurodegenerative disorders.